FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer

Erleada (apalutamide) is the first treatment approved for nonmetastatic, castration-resistant prostate cancer.If patients prescribed apalutamide are also taking other drugs metabolized by the same cytochrome P-450 isoenzyme systems, the circulating levels of apalutamide may be altered.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research